-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – OSU-6162
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry OSU-6162 Drug Details OSU-6162 (PNU-96391) is under development for the treatment of residual symptoms...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NS-2359
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NS-2359 Drug Details NS-2359 (GSK372475) is under development for the treatment of cocaine addiction....
-
Product Insights
Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity. The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The symptoms of Schizophrenia include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia pipeline market research report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Stroke can occur with symptoms including sudden numbness in their face or limbs, particularly down one side of their body. The sufferer may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance. The Stroke pipeline drugs market research report outlays comprehensive information on the Stroke targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA)...
-
Product Insights
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Idiopathic Pulmonary Fibrosis (IPF) symptoms include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness, and weight loss. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents, and anticoagulants. The IPF pipeline drugs market research report provides an analysis of the IPF drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...
-
Product Insights
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gamma-aminobutyric acid A receptor, alpha 2 or GABRA2 are activated by the major inhibitory neurotransmitter in the mammalian brain and has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control. The Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) pipeline drugs market research report outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) targeted therapeutics, complete with analysis by...